{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:07:48Z","timestamp":1768565268530,"version":"3.49.0"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>We have been encouraging practicing gynecologists to adopt molecular diagnostics tests, PCR, and cancer biomarkers, as alternatives enabled by these platforms, to traditional Papanicolaou and colposcopy tests, respectively. An aliquot of liquid-based cytology was used for the molecular test [high-risk HPV types, (HR HPV)], another for the PAP test, and one more for p16\/Ki67 dual-stain cytology. A total of 4499 laboratory samples were evaluated, and we found that 25.1% of low-grade samples and 47.9% of high-grade samples after PAP testing had a negative HR HPV-PCR result. In those cases, reported as Pap-negative, 22.1% had a positive HR HPV-PCR result. Dual staining with p16\/Ki67 biomarkers in samples was positive for HR HPV, and 31.7% were also positive for these markers. Out of the PCR results that were positive for any of these HR HPV subtypes, n 68.3%, we did not find evidence for the presence of cancerous cells, highlighting the importance of performing dual staining with p16\/Ki67 after PCR to avoid unnecessary colposcopies. The encountered challenges are a deep-rooted social reluctance in Mexico to abandon traditional Pap smears and the opinion of many specialists. Therefore, we still believe that colposcopy continues to be a preferred procedure over the dual-staining protocol.<\/jats:p>","DOI":"10.3390\/v16060887","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:19:46Z","timestamp":1717417186000},"page":"887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Findings and Challenges in Replacing Traditional Uterine Cervical Cancer Diagnosis with Molecular Tools in Private Gynecological Practice in Mexico"],"prefix":"10.3390","volume":"16","author":[{"given":"Jos\u00e9 L.","family":"Castrillo-Diez","sequence":"first","affiliation":[{"name":"Leire Genomic Laboratories, Le\u00f3n 37000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9815-2667","authenticated-orcid":false,"given":"Carolina","family":"Rivera-Santiago","sequence":"additional","affiliation":[{"name":"Columbia Biotec, Columbia Laboratories, Tlalpan 14090, Mexico"},{"name":"Columbia Laboratories, Basic Scientific Research Division, Mexico City 04000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia M.","family":"\u00c1vila-Flores","sequence":"additional","affiliation":[{"name":"Leire Genomic Laboratories, Le\u00f3n 37000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia A.","family":"Barrera-Barrera","sequence":"additional","affiliation":[{"name":"Innbiogem SC\/Vitagenesis SA at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEIDI) of CONACyT Vitaxentrum Group, Monterrey 64630, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo A.","family":"Barrera-Salda\u00f1a","sequence":"additional","affiliation":[{"name":"Columbia Laboratories, Basic Scientific Research Division, Mexico City 04000, Mexico"},{"name":"Innbiogem SC\/Vitagenesis SA at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEIDI) of CONACyT Vitaxentrum Group, Monterrey 64630, Mexico"},{"name":"Facultades de Medicina y Ciencias Biol\u00f3gicas, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, San Nicol\u00e1s de los Garza 66455, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.2023.13174","article-title":"Cervical Cancer Screening: A Review","volume":"330","author":"Perkins","year":"2023","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/(SICI)1097-0339(200001)22:1<52::AID-DC14>3.0.CO;2-#","article-title":"Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer","volume":"22","author":"Weintraub","year":"2000","journal-title":"Diagn. Cytopathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/dc.22842","article-title":"Gynecologic cytology on conventional and liquid-based preparations: A comprehensive review of similarities and differences","volume":"41","author":"Hoda","year":"2013","journal-title":"Diagn. Cytopathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2008.06.019","article-title":"Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries","volume":"26","author":"Cuzick","year":"2008","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000528931","article-title":"Overview of Ancillary Techniques in Cervical Cytology","volume":"67","author":"Olivas","year":"2023","journal-title":"Acta Cytol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programs and age-specific coverage estimates for 202 countries and territories worldwide: A review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_8","unstructured":"World Health Organization (2014). Comprehensive Cervical Cancer Control. A Guide to Essential Practice, World Health Organization. [2nd ed.]. WHO Library Cataloguing-in-Publication Data."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1028291","DOI":"10.3389\/fonc.2022.1028291","article-title":"The health system and access to treatment in patients with cervical cancer in Mexico","volume":"12","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clon.2021.06.013","article-title":"Eliminating Cervical Cancer: Progress and Challenges for High-income Countries","volume":"33","author":"Smith","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/GCO.0000000000000542","article-title":"The advent of human papillomavirus detection for cervical screening","volume":"31","author":"Morris","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1006038","DOI":"10.3389\/fmed.2022.1006038","article-title":"Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study","volume":"9","author":"Rol","year":"2022","journal-title":"Front. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ygyno.2006.08.053","article-title":"Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies","volume":"104","author":"Koliopoulos","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hareza, D.A., Wilczy\u0144ski, J.R., and Paradowska, E. (2022). Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031818"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Bello, J.O., Carrillo-Garc\u00eda, A., and Lizano, M. (2022). Epidemiology and Molecular Biology of HPV Variants in Cervical Cancer: The State of the Art in Mexico. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158566"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and clinical aspects of HPV-related cancers","volume":"17","author":"Scymonowicz","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","article-title":"2020 list of human papillomavirus assays suitable for primary cervical cancer screening","volume":"27","author":"Arbyn","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfill criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e3181e8b2c4","article-title":"Using biomarkers as objective standards in the diagnosis of cervical biopsies","volume":"34","author":"Galgano","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1586\/epr.12.13","article-title":"Biomarkers for cervical cancer screening: The role of p16(INK4a) to highlight transforming HPV infections","volume":"9","author":"Reuschenbach","year":"2012","journal-title":"Expert Rev. Proteom."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1309\/AJCPXSVCDZ3D5MZM","article-title":"Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia","volume":"133","author":"Bergeron","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/jcp.2010.078634","article-title":"p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions","volume":"63","author":"Dijkstra","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1309\/AJCP3CD9YKYFJDQL","article-title":"The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL papa cytology results","volume":"134","author":"Denton","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cncy.20140","article-title":"p16\/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: Results from the European equivocal or mildly abnormal Papanicolaou cytology study","volume":"119","author":"Schmidt","year":"2011","journal-title":"Cancer Cytopathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2011.02.033","article-title":"Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16\/Ki-67 Dual-stained cytology","volume":"121","author":"Petry","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-12-0270","article-title":"Performance of p16\/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population","volume":"18","author":"Wentzensen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/dc.21757","article-title":"Evaluation of CINtec PLUS\u00ae testing as an adjunctive test in ASC-US diagnosed SurePath\u00ae preparations","volume":"41","author":"Edgerton","year":"2013","journal-title":"Diagn Cytopathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejogrb.2017.01.009","article-title":"Diagnostic performance of dual-staining cytology for cervical cancer screening: A systematic literature review","volume":"210","author":"Tjalma","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/cncy.22631","article-title":"Utility of p16\/Ki67 double immunocytochemistry for detection of cervical adenocarcinoma","volume":"130","author":"Ryu","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-020-0920-9","article-title":"Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)","volume":"123","author":"Kyrgiou","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_32","first-page":"e41098","article-title":"Screening Guidelines and Programs for Cervical Cancer Control in Countries of Different Economic Groups: A Narrative Review","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"ref_33","unstructured":"World Health Organization (2020). Global Strategy to Accelerate the Elimination of Cervical Cancer as A Public Health Problem and Its Associated Goals and Targets for the Period 2020-2030, World Health Organization. Seventy-third World Health Assembly. Agenda item 11.4. WHO Library Cataloguing-in-Publication Data."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106900","DOI":"10.1016\/j.ypmed.2021.106900","article-title":"Worldwide use of HPV self-sampling for cervical cancer screening","volume":"154","author":"Serrano","year":"2022","journal-title":"Prev. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","article-title":"Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis","volume":"15","author":"Arbyn","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.lanepe.2022.100332","article-title":"HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer","volume":"14","author":"Arbyn","year":"2022","journal-title":"Lancet Reg. Health Eur."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:29Z","timestamp":1760107889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/6\/887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["v16060887"],"URL":"https:\/\/doi.org\/10.3390\/v16060887","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}